Vistagen Therapeutics, Inc. (VTGN)
0.2739
-0.02
(-7.15%)
USD |
NASDAQ |
Sep 25, 16:00
0.263
-0.01
(-3.98%)
After-Hours: 19:59
Vistagen Therapeutics Free Cash Flow : -62.38M for June 30, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -62.38M |
| March 31, 2026 | -66.59M |
| December 31, 2025 | -60.67M |
| September 30, 2025 | -53.96M |
| June 30, 2025 | -51.05M |
| December 31, 2024 | -39.36M |
| September 30, 2024 | -33.65M |
| June 30, 2024 | -28.89M |
| March 31, 2024 | -25.87M |
| December 31, 2023 | -26.12M |
| September 30, 2023 | -31.50M |
| June 30, 2023 | -41.67M |
| March 31, 2023 | -49.93M |
| December 31, 2022 | -58.04M |
| September 30, 2022 | -60.14M |
| June 30, 2022 | -55.28M |
| March 31, 2022 | -45.46M |
| December 31, 2021 | -35.18M |
| September 30, 2021 | -28.27M |
| June 30, 2021 | -15.86M |
| March 31, 2021 | -12.35M |
| December 31, 2020 | -9.621M |
| September 30, 2020 | -8.761M |
| June 30, 2020 | -13.80M |
| March 31, 2020 | -15.76M |
| Date | Value |
|---|---|
| December 31, 2019 | -16.74M |
| September 30, 2019 | -16.37M |
| June 30, 2019 | -16.29M |
| March 31, 2019 | -14.70M |
| December 31, 2018 | -13.74M |
| September 30, 2018 | -12.28M |
| June 30, 2018 | -10.10M |
| March 31, 2018 | -9.060M |
| December 31, 2017 | -7.979M |
| September 30, 2017 | -7.632M |
| June 30, 2017 | -7.962M |
| March 31, 2017 | -7.501M |
| December 31, 2016 | -7.310M |
| September 30, 2016 | -6.386M |
| June 30, 2016 | -5.684M |
| March 31, 2016 | -4.835M |
| December 31, 2015 | -4.398M |
| September 30, 2015 | -3.565M |
| June 30, 2015 | -2.580M |
| March 31, 2015 | -2.769M |
| December 31, 2014 | -2.342M |
| September 30, 2014 | -2.319M |
| June 30, 2014 | -2.406M |
| March 31, 2014 | -2.136M |
| December 31, 2013 | -2.643M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Onconetix, Inc. | -10.31M |
| ACADIA Pharmaceuticals, Inc. | 145.62M |
| Alnylam Pharmaceuticals, Inc. | 793.94M |
| Anika Therapeutics, Inc. | 0.562M |
| Savara, Inc. | -110.66M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -14.71M |
| Cash from Financing (Quarterly) | 0.909M |
| Free Cash Flow Per Share (Quarterly) | -0.3422 |
| Free Cash Flow to Equity (Quarterly) | -14.45M |
| Free Cash Flow to Firm (Quarterly) | -14.71M |
| Free Cash Flow Yield | -567.3% |